SHANGHAI, July 24 /PRNewswire-Asia-FirstCall/ -- Chemspec International Limited (NYSE:CPC) ("Chemspec" or the "Company"), a leading China-based contract manufacturer of highly-engineered specialty chemicals, today announced two recent senior management appointments: Dr. Jinhua (Jim) Chen was promoted to the vice president of process research and development, and Dr. Yuelie Lu was appointed as the vice president of pharmaceutical business development. Previously the director of research and development at Chemspec, Dr. Chen will continue to oversee process research and development at Chemspec. Prior to joining Chemspec in June 2008, Dr. Chen was an associate research investigator in the global pharmaceutical research and development division at Abbott Laboratories in Chicago, Illinois. Dr. Chen was also an American Chemical Society Industrial Innovation Award winner and a member of the teams at Abbott Laboratories which launched the drugs Ritonavir and Lopinavir. He holds a Ph.D. in organometallic chemistry from the University of New Brunswick in Canada and a B.S. in organic chemistry from Xiamen University in the People's Republic of China. Dr. Lu was recently hired as the vice president of pharmaceutical business development to oversee the expansion of our business related to pharmaceutical chemicals and the operation of our certified good manufacturing practices ("cGMP") facilities. Prior to joining Chemspec, Dr. Lu held a broad range of responsibilities at multiple pharmaceutical companies in the United States, with his two most recent positions being an associate director of chemical development at Lexicon Pharmaceuticals in New Jersey and a principle scientist at Amgen Inc. in California. Dr. Lu holds a Ph.D. from Purdue University and a B.S. from the University of Science & Technology of China. "Dr. Chen and Dr. Lu both bring additional knowledge and operational expertise to our management team," commented Dr. Jianhua Yang, chairman and CEO of Chemspec. "Dr. Chen has 12 years of experience in cGMP manufacturing. Over the past year at Chemspec, Dr. Chen has led the process research and development team to provide high-quality, efficient and environmentally-friendly services to our customers. Dr. Lu brings us his extensive experience in contract manufacturing project management and cGMP regulation compliance that will facilitate the expansion of our business related to pharmaceutical chemicals." Safe Harbor Statements This announcement contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in Chemspec's filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1, as amended from time to time. Chemspec does not undertake any obligation to update any forward-looking statement, except as required under applicable law. About Chemspec Chemspec is a leading China-based contract manufacturer of highly engineered specialty chemicals and the largest manufacturer of fluorinated specialty chemicals in China based on sales. In manufacturing specialty chemicals, Chemspec also provides process design and process development services, which enable efficient and rapid production of specialty chemicals that are incorporated into the products of Chemspec's end users. Chemspec's customers and end users include electronics, pharmaceutical and agrochemical companies. For more information, please visit http://www.chemspec.com.cn/ . For further information, please contact: Chemspec International Ltd. In Shanghai Bing Zhu Chief Financial Officer Tel: +86-21-5270-2636 x8053 Email: Christensen In New York Kathy Li Tel: +1-212-618-1978 Email: In Hong Kong Tip Fleming Tel: +852-9212-0684 Email: DATASOURCE: Chemspec International Limited CONTACT: Chemspec International Ltd.: In Shanghai: Bing Zhu, Chief Financial Officer at +86-21-5270-2636 x8053 or ; Or Christensen: In New York: Kathy Li at +1-212-618-1978 or ; In Hong Kong: Tip Fleming at +852-9212-0684 or Web site: http://www.chemspec.com.cn/

Copyright